Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
32.01 USD +2.93% Intraday chart for Neurogene Inc. +5.57% +65.17%
06-18 Neurogene Doses First Patient in High-Dose Group of Rett Syndrome Trial MT
06-18 Neurogene Inc. Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurogene : Corporate Presentation June 2024
PU
Neurogene : IRSF Clinical Safety Poster
PU
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
BU
Neurogene to Participate in Upcoming Conferences
BU
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
BU
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
AQ
Neurogene: Q1 Earnings Snapshot
AQ
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
BU
Neurogene : ASGCT NGN-401 Clinical Safety Poster
PU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
BU
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
BU
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
BU
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
BU
Neurogene to Participate in Upcoming Investor Conferences
BU
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
BU
Neurogene Announces Business Update and 2024 Outlook
BU
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
AQ
Neoleukin Therapeutics : Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome - Form 8-K
PU
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
AQ
Neoleukin: Q3 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. News Neurogene Inc.
  5. Press Releases